New #ISEPpapers! Shining the spotlight on the neglected: new high-quality #genome assemblies as a gateway to understanding the evolution of Trypanosomatidae https://bmcgenomics.biomedcentral.com/articles/10.1186/s12864-023-09591-z #protists #parasites #microbes #genomics #microbiology #genomes #science #trypanosoma by Amanda Albanaz et al.

@PeerCommunityIn now published in Peer Community Journal, #Infections section: Whole blood transcriptome profiles of trypanotolerant and trypanosusceptible cattle highlight a differential modulation of metabolism and immune response during infection by #Trypanosoma congolense https://peercommunityjournal.org/articles/10.24072/pcjournal.239/ https://doi.org/10.24072/pcjournal.239

Preliminary sketch of Trypanosoma theileri. Trying to recreate lost micrograph of a specimen whipping a RBC with flagellum until it burst. #sciart #trypanosoma #vetmed

A new #preprint #OpenScience #PeerReview by #PCI_Infections: Peylhard M, Berthier D, Dayo G-K, Chantal I, Sylla S, Nidelet S, Dubois E, Martin G, Sempéré G, Flori L, Thévenon S (2022) Whole blood transcriptome profiles of trypanotolerant and trypanosusceptible cattle highlight a differential modulation of metabolism and immune response during infection by #Trypanosoma congolense. #bioRxiv. https://doi.org/10.1101/2022.06.10.495622

"It can be between 10 and 30 years before people develop symptoms so most are unaware they have Chagas, often called a “silent and silenced disease”. Some will never develop symptoms but up to a third suffer heart damage, which can lead to progressive heart failure or sudden death. Others (up to 10%) may experience abnormal enlargement of the colon or oesophagus.

About 12,000 people die from Chagas every year. It kills more people in Latin America than any other parasitic disease, including malaria."

#Parasitology #Immunology #PublicHealth #ChagasDisease
#Trypanosoma #Tcruzi

https://www.theguardian.com/global-development/2023/jan/16/the-silent-disease-chagas-is-a-killer-now-carriers-want-their-voices-heard

Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by #Trypanosoma brucei gambiense: a multicentre, open-label, single-arm, phase 2/3 trial

https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00660-0/fulltext?dgcid=raven_jbs_aip_email#.Y48F0DKK7dA.twitter

New research article in The Lancet Infectious Diseases> Efficacy and safety of #acoziborole in patients with human African #trypanosomiasis caused by #Trypanosoma brucei gambiense: a multicentre, open-label, single-arm, phase 2/3 trial https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00660-0/fulltext #gambienseHAT #SleepingSickness

Paper alert🚨!

Intracellular #Trypanosoma cruzi amastigotes retain a short flagellum, which for first time has been obsevced beating within another eukaryotic cell!

#protists #parasites #MicrobialEukaryotes

https://www.biorxiv.org/content/10.1101/2022.11.23.517661v1?rss=1